Daiichi Sankyo Venture Subsidiary Focuses On Rare Disease Niche
This article was originally published in PharmAsia News
Executive SummaryKobe-based Asubio Pharma, a venture firm and subsidiary of Daiichi Sankyo has turned its attention to the research and development of treatments and diagnostics for rare diseases
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.